Renowned gi oncology leader dr. richard goldberg joins agenus as chief development officer

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in immuno-oncology innovation today announced that dr. richard m. goldberg, an internationally recognized expert in gastrointestinal (gi) cancer treatment and research, has joined the company as chief development officer. in this role, dr. goldberg will lead efforts to advance the botensilimab/balstilimab (bot/bal) program for patients and guide the company's regulatory and development strategy as it prepares to re-engage g.
AGEN Ratings Summary
AGEN Quant Ranking